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A new biocompatible delivery scaffold containing heparin 
and bone morphogenetic protein 2
Silicon-substituted calcium phosphate (Si-CaP) was devel-
oped in our laboratory as a biomaterial for delivery in bone 
tissue engineering. It was fabricated as a 3D-construct of 
scaffolds using chitosan-trisodium polyphosphate (TPP) 
cross-linked networks. In this study, heparin was covalently 
bonded to the residual –NH2 groups of chitosan on the scaf-
fold applying carbodiimide chemistry. Bonded heparin was 
not leached away from scaffold surfaces upon vigorous 
washing or extended storage. Recombinant human bone 
morphogenetic protein 2 (rhBMP-2) was bound to conjugat-
ed scaffolds by ionic interactions between the negatively 
charged SO42– clusters of heparin and positively charged 
amino acids of rhBMP-2. The resulting scaffolds were in-
spected for bone regenerative capacity by subcutaneous im-
planting in rats. Histological observation and mineraliza-
tion assay were performed after 4 weeks of implantation. 
Results from both in vitro and in vivo experiments suggest 
the potential of the developed scaffolds for bone tissue engi-
neering applications in the future.
Keywords: heparin, carbodiimide, rhBMP-2, delivery scaf-
fold, bone tissue engineering
A critical size defect in bone is defined as a defect that will not heal without interven-
tion (1). Bone tissue engineering is a strategy for completing bone regeneration in case of 
such defects. It relies on the complex interplay between cells, biomaterials and biomodula-
tors, in intimate synergy with the hosts’ biological capabilities. Unlike enamel and dentin, 
bone is a very dynamic tissue because modeling and remodeling processes occur simulta-
neously. Modeling is concerned with changes in bone shape, while remodeling implies bone 
turnover without shape modification. These operations take place through an organized 
sequence of events at the same anatomical location and are regulated by osteoblast and 
osteoclast activities, respectively (2). A variety of biomaterials have been developed to elicit 
an adequate response from the biological milieu. The response, if insufficient, may contrib-
ute to poor reactivity within direct contact of the damaged tissues, resulting in non-union.
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Bone morphogenetic proteins (BMPs) were introduced into clinical practice in the late 
1990s, but only some have the potential to induce formation of new bone (3). BMP-2, trade 
name INFUSE® (Medtronic, MN, USA), received approval of US-FDA in 2002 for restricted 
use in the treatment of open tibial fractures and spinal fusion. However, it is often used off 
label to stimulate bone defect healing, not only in the upper and lower extremities but in 
craniofacial surgery as well. Regrettably, FDA issued a warning about the protein product 
six years later concerning the troublous formation of bone in unwanted locations, and the 
potential to fuel the growth of cancer cells or spark adverse immune system reactions (4–6).
Use of scaffolds as a delivery system in bone tissue engineering is advantageous, be-
cause they can release an active agent in the exact area requested over a sustained period 
of time and can prevent leaching away of the entrapped compound from the desired site 
into the surrounding tissues (7, 8). Moreover, biomaterials as scaffold compositions can be 
optimized to support basic cellular functions by establishing an adequate framework for 
specific cell adhesion, proliferation and differentiation, leading to improved bone growth. 
Partial substitution of silicon (Si) atoms in crystal lattices of calcium phosphate (CaP) 
served as a rationale for enhancing bone regenerative capacity of biomaterials like CaP 
compounds (9). According to this scheme, new Si-substituted CaP, namely 0.4Si-synHA, 
has been synthesized in our laboratory and successfully used as a delivery scaffold for 
vancomycin (10). In fact, these scaffolds can be proposed for critical bone injury if bone 
related growth factors are coexistent and their sustained release characteristics are achiev-
able. A new delivery system bearing recombinant human BMP-2 (rhBMP-2) was thus de-
veloped in this study. Carbodiimide chemistry was applied for bonding heparin to the 
scaffolds by ionic interactions to create rhBMP-2 binding sites (11). Therefore, it was essen-
tial (i) to determine the feasibility and efficiency of the coupling reaction when it was first 
applied to pair heparin and chitosan bearing scaffolds, (ii) to assess the binding affinity 
and release property of rhBMP-2 to and from the scaffolds in vitro, and (iii) to verify the 
ability of the scaffolds in bone regeneration in vivo. All approaches introduced are aimed 
at acquiring biocompatible rhBMP-2 delivery scaffolds for effective bone regeneration ca-
pacity of critical bone defects.
EXPERIMENTAL
Materials, chemicals, assay kits and accessories
The Si-substituted CaP compound 0.4Si-synHA was synthesized in our laboratory 
according to the procedures described previously (10). It was fabricated as a 3D-construct 
of scaffolds and was used throughout the study. Chitosan from crab shells (Mr 140,000–
200,000, deacethylation degree ~80 %) was a commercial product of Sigma (USA). Sodium 
tripolyphosphate (TPP) was acquired from Sigma-Aldrich (Germany). Heparin (Mr ~5000) 
and chemicals for the heparin conjugation process, N-(3-dimethyl aminopropyl)-N’-
ethylcarbodiimide hydrochloride (EDC), N-hydroxysuccinimide (NHS), and 2-morpholi-
no-ethane sulfonic acid (MES), were purchased from Sigma. rhBMP-2 was supplied in a 
homodimeric form (Mr. 26 000) by BioVision (USA). Bovine serum albumin (BSA) was ob-
tained from Sigma-Aldrich. Staining dyes, including hematoxylin/eosin (H&E) and aliza-
rin red S, were also purchased from Sigma-Aldrich. Other chemicals were of analytical 
grade and were acquired from Merck (Germany). The Quantikine® BMP2 ELISA kit was a 
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commercial product of R&D Systems (USA), and the mineralization assay kit was supplied 
by Interchim (USA). A 250-µL measuring micro-syringe (Hamilton®) was obtained from 
Hamilton Company (USA).
Preparation of scaffolds
Five grams of 0.4Si-synHA powder were triturated with 1 mL of chitosan solution 
(1.5 % m/V in 3 % V/V acetic acid) until a smooth paste was obtained. The paste was mold-
ed into an open-end plastic tube of 5 mm diameter × 3 mm length and left at room tem-
perature to dry. Dried paste in the mold was immersed in sodium tripolyphosphate (TPP) 
solution (1 % m/V in 3 % V/V acetic acid) at room temperature for 24 h to allow crosslinking 
of chitosan and TPP (12). After that, the plastic mold was carefully trimmed out and the 
scaffold was thoroughly washed with distilled water. Any trapped water in the scaffold 
was removed by freeze-drying (ROCTEC, Hong Kong). A scaffold of an average mass of 
0.4 g was obtained. It was stored at 4 °C until use unless otherwise stated.
Conjugation of heparin onto the scaffold
MES buffer was prepared by dissolving 0.433 g EDC and 0.157 g NHS in 188.3 mL 
water and adjusted to pH 5.4. A certain amount of heparin was dissolved in this buffer to 
a concentration of 1, 2, or 4 mmol L–1. Before use, the MES buffer and heparin solutions 
were sterilized by filtering through a 0.2-µm membrane filter. Twelve pieces of prepared 
scaffolds, total mass 5 g, were sterilized by soaking in 70 % ethanol for 1 h, left to air-dry, 
and subsequently incubated in the MES solution for 30 min for activation. After being re-
moved and placed on a sterile paper to discard any residual buffer, a group of four pieces 
of these activated scaffolds were immersed in a tube containing 200 µL of heparin solution. 
The existing air bubble was evacuated using a vacuum pump at 200 Pa for 30 s, and incuba-
tion was carried out at 37 °C for a further 4 h. Excess supernatant was then fully drawn out 
using a 250-µL measuring micro-syringe and stored at 4 °C until use for determination of 
unreacted heparin. The scaffold was washed with a series of sterile sodium chloride solu-
tions (i.e., 2 mol L–1, 6 times for 4 h, and 4 mol L–1, 4 times for 6 h) and then with sterile 
water (3 times for 8 h). After freeze-drying, the heparin-conjugated scaffolds were kept in 
a sterile container at 4 °C until use. Each experiment was performed in triplicate.
Characterization of the heparin-conjugated scaffold
Contents of conjugated heparin. – Heparin bound on the conjugated scaffold was quali-
tatively investigated using the toluidine blue method (13). Briefly, 0.4 mg mL–1 toluidine 
blue solution in 0.1 mol L–1 hydrochloric acid containing 0.2 % m/V sodium chloride was 
prepared. The test scaffold was immerged in the dye solution for 4 h at room temperature 
under gentle agitation using a vortex. The scaffold was then removed, placed on filter pa-
per to give up excess dye, washed with distilled water (2 times for 5 min), and air-dried. 
The stained scaffold was photographed using a Canon PowerShot G3X camera.
The method of Smith et al. (14) was applied for precise determination of the heparin 
content bound on the scaffold. 50 µL of the collected supernatant was added to a test tube 
containing 950 µL of toluidine blue solution (prepared as described above) and incubated 
at room temperature for 30 min under gentle shaking. Four milliliters of n-hexane was 
376
S. Thanyaphoo and J. Kaewsrichan: A new biocompatible delivery scaffold containing heparin and bone morphogenetic protein 2, 
Acta Pharm. 66 (2016) 373–385.
 
then added and mixed for 30 s using a vortex, followed by centrifugation at 2,000 rpm for 
2 min. The aqueous layer was aspirated, diluted 1:10 with ethanol, and OD630 was mea-
sured within 30 min. The heparin calibration curve was prepared as follows. Varying 
volumes of 2 mmol L–1 heparin solution were separately added to each of 5 tubes contain-
ing 950 µL of toluidine blue solution and the volume of 1 mL was made up by addition of 
0.2 % m/V sodium chloride. The following steps were performed in a similar ways as de-
scribed previously. Heparin content per scaffold was calculated taking into account the 
concentration of heparin solution before and after incubation with the scaffolds.
Stability of conjugated bonds. – Pig whole blood was obtained from the slaughter-house 
authorized by the Faculty of Natural Resources, Prince of Songkla University. A fraction, 
called platelet-rich plasma (PRP), was prepared by mixing 1 volume of blood and 9 vol-
umes of 3.8 % m/V tri-sodium citrate solution in a plastic tube. The PRP jelly was separated 
by centrifugation at 1300 rpm for 10 min at 4 °C. The heparin-conjugated scaffold was 
shaken vigorously in PBS and PBS was collected for the assay of heparin bonding stability. 
The collected PBS was incubated with the PRP for 30 min at 37 °C under static conditions. 
Clotting appearance was visually observed and recorded as ++, + or – for truly clotted, 
slightly clotted or unclotted status of the PRP.
Loading of rhBMP-2
rhBMP-2 protein was reconstituted to a concentration of 1 mg mL–1 (38.5 mmol L–1) in 
water containing 50 mg mL–1 BSA according to the manufacturer’s recommendation. This 
solution was further diluted to a concentration of 0.4 or 0.8 µmol L–1 in PBS, filter sterilized 
and stored in aliquot amounts at –20 °C until use. Four pieces of conjugated scaffolds in 
each defined group were continually used for rhBMP-2 loading. One day before implanta-
tion, the scaffolds were immersed in a tube containing 200 µL of rhBMP-2 solution and 
incubated at 4 °C for an additional 24 h. Excess protein solution was completely drawn out 
using a micro-titrating syringe and stored at 4 °C until use for determination of the 
amounts of unbound rhBMP-2. The obtained scaffolds were subsequently transplanted 
into rats. Each experiment was done in triplicate.
Characterization of rhBMP-2 loaded scaffolds
Determination of bound rhBMP-2. – The amount of rhBMP-2 bound to each scaffold was 
indirectly assayed in the excess protein solution collected using the Quantikine® BMP-2 
ELISA kit. In brief, 100 µL of the test solution was added to a well of BMP-2 antibody 
precoated microplate and incubated for 2 h at room temperature. Added solution was 
then removed and the well was washed 4 times with washing buffer, followed by the ad-
dition of horseradish peroxidase conjugated BMP-2 antibody. After 2 h of incubation at 
room temperature, the antibody solution was aspirated and the well was completely 
washed with washing buffer. Then, tetramethylbenzidine substrate was added and incu-
bated for 30 min in the dark before stop solution was added to terminate the reaction. The 
OD450 was measured within 30 min. The BMP-2 standard curve was prepared according 
to the manufacturer’s recommendation. The rhBMP-2 content per scaffold was calculated 
taking into account the concentration of rhBMP-2 solution before and after incubation 
with scaffolds.
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Release of rhBMP-2 in vitro. – The release of rhBMP-2 from finished scaffolds was per-
formed in PBS at 4 °C under static conditions. Briefly, four pieces of these scaffolds in each 
defined group, total mass ~2 g, were immersed in each of six tubes containing 500 µL of 
PBS. The tubes were separately incubated at 4 °C without agitation for a desired time pe-
riod of 3, 7, 10, 14, 28 or 45 days. At each specified time period, 100 µL of the supernatant 
were aspirated and stored at 4 °C until use. The amount of rhBMP-2 released from the scaf-
folds was determined using the ELISA kit. Results were calculated by comparison with the 
standard curve and were reported as % release.
Animals, surgical procedure and implantation
The experiment involving animals was approved by the PSU animal care and use 
committee of the Prince of Songkla University. Four male 8-week-old Wistar rats (mass 
220–250 g) were anesthetized by intramuscular injection of the mixture containing a 1:1 
volume ratio of xylazine (25 mg mL–1) and zoletil (12.5 mg mL–1) at a dose of 100 µL per 100 
g body mass. The animal lumbar area was disinfected and shaved. Seven pockets, each 6 
mm wide, were created and a test implant was inserted into each. Seven different groups 
of implants were formed according to the concentrations of heparin and rhBMP-2 was used 
in the conjugation reaction and the loading process. The groups included Gr.1, 0/0; Gr. 2, 
1/0; Gr. 3, 1/0.4; Gr. 4, 1/0.8; Gr. 5, 2/0; Gr. 6, 2/0.4; and Gr. 7, 2/0.8, where the first number was 
heparin concentration in mmol L–1 and the last number was rhBMP-2 concentration in 
µmol L–1. The wounds were closed using 4–0 silk sutures and a topical antibiotic was ap-
plied to operated rats for 1 week.
Histological analysis
After 4 weeks of implantation, the animals were sacrificed and the implants were 
excised. The excised implant was fixed in 10 % V/V formaldehyde in PBS for 24 h and de-
calcified in 1 mol L–1 HCl saturated with EDTA for 2 days. The decalcified sample was 
paraffin embedded, sectioned to 5-µm thick layers, and separately stained with hematoxy-
lin/ eosin (H&E) and alizarin red S. Three different levels of each section were collectively 
analyzed using Cell P Software on a light microscope (Olympus).
Mineralization assay
All forms of calcium deposited on a sectioned implant were quantitatively deter-
mined using the Interchim mineralization assay kit after alizarin red S staining. The 
stained sample was placed in a well of a 24-well plate and incubated with 500 µL of stain 
solubilizing solution for 10 min. Then, 150 µL of the supernatant was transferred to a well 
of a 96-well plate, repeated three times and measured for OD405. The dye standard curve 
was prepared using alizarin red S in a concentration range of 5–500 µg mL–1. Results were 
calculated by comparison with the dye standard curve and reported in µg mL–1 of alizarin 
red S stained per section.
Statistical analysis
Data were presented as means ± standard deviation (SD) with n = 3 for the in vitro 
experiments, and n = 6 for the in vivo study. Statistical analyses were carried out by ANO-
378
S. Thanyaphoo and J. Kaewsrichan: A new biocompatible delivery scaffold containing heparin and bone morphogenetic protein 2, 
Acta Pharm. 66 (2016) 373–385.
 
VA (analysis of variance) using the Statistics Package for Social Science (SPSS) software. 
Differences were considered statistically significant at p < 0.05. All histological analyses 
were performed by two independent observers.
RESULTS AND DISCUSSION
Conjugation efficiency and stability of heparin conjugates
Chitosan (pKa 6.3) is polycationic when dissolved in acids and presents –NH3+ sites, 
while TPP dissociated in acids gives phosphoric anions. Hence, in acidic pH, these oppo-
sitely charged moieties can be associated by ionic interactions (12). For this reason, a 3D-
construct of scaffolds was created in the present study. With the chitosan to TPP concentra-
tion ratio as specified, some –NH3+ groups of chitosan remained unreacted and became 
–NH2 when the acid was washed off with distilled water (15). In the MES buffer containing 
EDC and NHS reagents, residual –NH2 groups of chitosan and –COOH groups of added 
heparin were activated and concurrently conjugated, forming surfaced heparin scaffolds 
according to the carbodiimide chemistry principle (16). The resulting products were later 
named conjugated scaffolds. In fact, this chemical reaction was employed to bridge hepa-
rin with gelatin (17) and heparin with collagen (18). Interestingly, it was first applied in this 
study for bonding heparin to chitosan present on the scaffolds.
The toluidine blue method developed by Dick et al. was chosen for qualitative deter-
mination of surfaced heparin, because it not only gives specific and homogeneous stain 
but is also less sensitive to artifacts (13). Results are shown in Fig. 1. The control was free 
of heparin conjugation and was not stained with the dye (Fig. 1a). Indeed, the dye specifi-
cally stained the heparin containing samples with homogeneous dye color (Fig. 1b–d). 
Besides the suggested benefits of the staining system, this might be due to the high poros-
ity of the scaffolds (10) by which diffusion and penetration of the dye through the scaffold 
structure was facilitated. Stained color intensity was higher for the samples using 2 mmol 
L–1 heparin for conjugation (Fig. 1c) compared to those using 1 mmol L–1 heparin (Fig. 1b). 
However, by increasing heparin concentration to 4 mmol L–1, stained color intensity was 
inversely decreased (Fig. 1d). The unexpected outcome could be explained in terms of the 
intrinsic properties of the coupling system and heparin. These include (i) the absence of 
spacers protruding from scaffold surfaces when applying carbodiimide chemistry for 
heparin conjugation (19), and (ii) a relatively large and complex structure containing nu-
merous scattered disaccharide units of heparin (20). Consequently, grafting of heparin 
Fig. 1. Representative photographs of the heparin conjugated scaffolds stained with toluidine blue: 
a) the no-heparin containing scaffold, b) scaffolds processed using 1 mmol L–1, c) 2 mmol L–1 and 
d) 4 mmol L–1 heparin solution.
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onto scaffold surfaces might be ineffective, hindered and further prevented when heparin 
concentrations are progressively increased, leading to a reduction of surface bound hepa-
rin (21) and thereby diminution of dye staining, as shown in Fig. 1d. Using the quantitative 
method of Smith et al. (14), approximately 18–61 nmoles heparin binding to each scaffold 
were determined. These values corresponded to 30–37 % binding efficiency (Table I). 
Again, increased binding efficacy was not directly proportional to the heparin concentra-
tion initially added in the conjugation reaction. To explain this, the rationales described 
previously could be applied. Consequently, the concentration of 4.0 mmol L–1 heparin was 
not further taken into consideration.
Heparin is an anticoagulant. The stability of heparin bonding was then tested to as-
certain blood compatibility of the conjugated scaffolds using the PRP assay. Results are 
shown in Table I, indicating that complete clotting of PRP was visualized in all the test 
samples. This was due to no heparin present, estimating that leaching away of surfaced 
heparin into the shaken medium did not occur. Thus, the newly formed covalent bonds 
were satisfactorily stable, providing blood compatible carriers for growth factors. More-
over, distortion of the scaffold’s 3D-structure was not detected after immersion in PBS for 
4 weeks or in the process of heparin conjugation (data not shown).
Loading and release of rhBMP-2
To reduce loss of rhBMP-2 activity, the supplied protein was first reconstituted in 
water containing BSA using the aseptic technique. This stock solution could then be di-
luted with other aqueous buffers and stored at 4 °C for 1 week or at –20 °C for future ap-
plications. In this study, the protein stock solution was diluted to a concentration of 0.4 or 
0.8 µmol L–1 in PBS and subsequently employed in the loading experiment. Through sim-
ple incubation, interactions between the added rhBMP-2 and conjugated heparin on scaf-
folds took place. To obtain uniform and reproducible loading, four pieces of conjugated 
scaffolds in each of the defined groups were immersed in 200 µL of rhBMP-2 solution and 
incubated for 24 h at 4 °C. Heat induced inactivation of the protein was expected to de-




























































































































1.0 1 0.84 ± 0.08 0.63 ± 0.029 0.37 ± 0.007 18.5 ± 0.4 37.0 ± 0.7 ++
2.0 2 1.75 ± 0.13 1.31 ± 0.061 0.69 ± 0.015 34.0 ± 0.8 34.5 ± 0.8 ++
4.0 4 3.70 ± 0.22 2.78 ± 0.130 1.22 ±0.032 61.0 ± 1.6 30.5 ± 0.8 ++
a Four scaffolds were incubated in 200 µL of heparin solution.
b The volume of heparin solution drawn out using a measuring microliter syringe after 4 h of incubation.
c Symbols: ++, + or -indicates truly clotted, slightly clotted or un-clotted status of the PRP, respectively.
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crease when manipulating it at such a low temperature. Results in Table II show that there 
were 11.7 and 29.8 pmol of rhBMP-2 bound to each scaffold, corresponding to 58.6 and 
74.5 % loading efficiency for the initial loading concentration of 0.4 and 0.8 µmol L–1, re-
spectively. It was noted that by increasing the initial protein concentration, increased bind-
ing efficacy was observed, but it was not proportional to the initial protein concentration. 
The amounts of heparin conjugated on a scaffold were most likely in excess compared to 
that of the bound protein (see Tables I and II). Thus, it might not be crucial for the protein 
to compete for its binding sites. Although more than 70 % of rhBMP-2 in the 0.8-µmol L–1 
solution could interact with surfaced heparin, its binding capacity seemed to be limited. 
Structural information for heparin, BMP-2, and heparin-BMP-2 complexes could be the 
rationale for explaining the restricted efficiency (22). Heparin is a compound of glycoami-
noglycans, which are structurally heterogeneous (23). Native BMP-2 is a homodimeric pro-
tein. The BMP-2 subunits are assembled at an angle of approximately 40°; the angle is 
fairly constant, being stabilized by hydrophobic interactions that take place between these 
subunits. The N-terminuses of both monomers contain additional five positively charged 
amino acid residues and function as heparin binding sites (22). The specific affinity of 
BMP-2 to heparin is then essential for storage, release and protection of the protein from 
heat, pH and enzymatic degradation (11, 24, 25). Motions of these terminuses are found to 
be scattered. However, angled monomers are forced to adopt a wider conformation when 
binding to heparin. Accordingly, changes of rhBMP-2 conformations interacting with hep-
arin on the scaffold might influence the binding affinity for the upcoming protein, ulti-
mately causing such a binding constraint (26).
To imitate the long curing course of most bone fractures, the release of rhBMP-2 from 
the prepared scaffolds was investigated in PBS for 45 days at 4 °C. In contrast to this study, 
most researches have explored the release of proteins from delivery systems at 37 °C and 
often over a shorter time period (27, 28). In fact, during the loading and characterization of 
the release of rhBMP-2, it is important to ensure that the protein is always in its active form. 
The temperature of 4 °C was thus specified for the investigations in this project, based on 
the manufacturer’s recommendation. Results indicate that there was no burst release of 
rhBMP-2 (Fig. 2). 50 % of the protein was released after 2 weeks of incubation in PBS, and 
more than 90 % of the protein was released after 45 days. Therefore, the in vitro results 















































































































0.4 2.08 0.18 ± 0.04 0.86 ± 0.023 1.22 ± 0.006 11.73 ± 0.06 58.7 ± 0.3
0.8 4.16 0.22 ± 0.04 1.06 ± 0.023 3.10 ± 0.007 29.81 ± 0.06 74.5 ± 0.2
a Four heparin-conjugated scaffolds were incubated in 200 µL of rhBMP-2 solution.
b The volume of rhBMP-2 solution being drawn out using a microliter syringe after 24 h of incubation.
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suggested a sustained release pattern of the rhBMP-2. For true translation of the in vitro 
data, experiments of biocompatibility and bone regenerative capacity of the established 
scaffolds will be carried out using a rat model.
Biocompatibility and in vivo osteoinductive capacity of the rhBMP-2 containing 
scaffolds
The rhBMP-2 loaded scaffolds were investigated for biocompatibility and bone regen-
erative capacity by being subcutaneously implanted in rats. Histological analysis was car-
ried out after 4 weeks of implantation. Sectioned implants were stained with H&E and 
alizarin red S, by which the newly formed bone tissue could be distinguished from other 
soft tissues remaining in the sections. Results are shown in Fig. 3. No presence of macro-
phage infiltration or tissue inflammation surrounding the implanted sites was found, in-
dicating that the protein delivery system developed in this work was biocompatible and 
non-toxic. In case of scaffolds lacking both heparin and rhBMP-2, new bone formation was 
absent (Fig. 3, Gr. 1). Instead, for the scaffolds with an identical amount of heparin conju-
gates, the amount of newly formed bone was increased in association with increased 
amount of bound rhBMP-2 (see Gr. 2–4 and Gr. 5–7).
The Interchim® assay kit was used for precise determination of the amounts of calci-
um deposited on histological sections. Results are reported as the degree of mineralization 
in Fig. 4. Mineralization was not apparent for the samples lacking both heparin and rh-
BMP-2 (Gr. 1). For the implants containing only heparin conjugates, high mineralization 
was consistent with the high heparin content (Gr. 2 and Gr. 5). As demonstrated, an ap-
proximately 2-fold increase of mineralization was observed for the Gr. 5 implants com-
pared to those of Gr. 2. Moreover, for the heparin-rhBMP-2 bearing implants, more im-
provement of calcium deposition was clearly observed (Gr. 3–4 and Gr. 6–7). Therefore, 
ectopic bone formation was successfully induced by a minute amount of rhBMP-2 released 
into the surrounding tissues of the implant sites (Fig. 2). In contrast, a systemic infusion 
Fig. 2. Release profile of rhBMP-2 from the developed scaffolds in PBS.
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dose of 2 µg kg–1 day–1 rhBMP-2 in rats did not show any significant inducing effects on 
serum osteocalcin levels and bone formation (29). However, larger animals are presumed 
to require greater amounts of BMP-2 for effective osteogenesis than those utilized by small 
Fig. 3. Representative photographs of sectioned implants after hematoxylin/eosin (H&E) and alizarin 
red S staining. Test scaffolds were subcutaneously implanted in rats and excised after 4 weeks. Seven 
groups of scaffold samples were assigned, with regard to the heparin concentration used in the conjuga-
tion process (1 or 2 mmol L–1) and that of rhBMP-2 for subsequent loading (0.4 or 0.8 µmol L–1). The 
scale bar indicates 500 µm.
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animals. Comparable bone regenerative capacity of BMP-2 for spinal fusion in dogs has 
been documented in two different strategies, viz., local application of a dose of 2.3 mg 
protein at the surgery site and implantation of a collagen scaffold containing 58–920 µg 
protein (30). Thus, to achieve a satisfactory outcome regarding bone regeneration by BMP-
2, protein doses combining local and systemic administration or that to be incorporated in 
a simple delivery carrier are distinctively higher than those employed in this research.
CONCLUSIONS
As shown in this study, development of scaffolds as delivery systems for critical bone 
injury is significantly advanced. Scaffolds were constructed by incorporating the Si-CaP 
powder inside the cross-linked networks of chitosan and TPP. In MES buffer containing 
EDC and NHS reagents of the carbodiimide reaction, the residual –NH2 ends of chitosan 
on the scaffolds and the –COOH ends of heparin were activated and concurrently bonded, 
resulting in scaffolds with surfaced heparin. These newly formed bonds were stable dur-
ing vigorous washing and extended storage of at least 4 weeks. Binding of rhBMP-2 and 
the conjugated heparin by ionic interactions occurred after soaking this scaffold in a pro-
tein solution. The bioactivity of rhBMP-2 could be preserved, since the protein was not 
confronted with any harsh conditions. Sustained release of rhBMP-2 was indicated in vitro, 
and its released amounts in vivo were sufficient to induce bone regeneration. There were 
no signs of complications at implanted sites, suggesting that the heparin-rhBMP-2 bearing 
scaffolds developed in this study were biocompatible, osteoinductive and cost effective.
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